Last reviewed · How we verify
RPC4046
At a glance
| Generic name | RPC4046 |
|---|---|
| Sponsor | Celgene |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis (PHASE3)
- A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis (PHASE3)
- A Study to Evaluate the Safety and Tolerability of Cendakimab in Chinese Healthy Participants (PHASE1)
- A Study to Evaluate the Drug Levels of Cendakimab Delivered Subcutaneously in Healthy Participants (PHASE1)
- Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RPC4046 CI brief — competitive landscape report
- RPC4046 updates RSS · CI watch RSS
- Celgene portfolio CI